Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera versus no ESA therapy for post-kidney transplant anemia in CKD
2007-003955-35Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Epoetin alfa RB in anemia of renal disease and anaemia (2 arms), sponsored by Roche. Primary endpoint: Primary efficacy endpoint. Started Oct 2007; status: completed.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia of renal diseaseanaemia
Beyond the preview
Go deeper on 2007-003955-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003955-35.